Gene expression pathways of high grade localized prostate cancer

Prostate

Volumn 71, Issue 14, 2011, Pages 1568-1577

  Ross, Ashley E ^a   Marchionni, Luigi ^a   Vuica Ross, Milena ^a   Cheadle, Chris ^a   Fan, Jinshui ^a   Berman, David M ^a   Schaeffer, Edward M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gleason score; high risk prostate cancer; laser capture micro dissection; microarray analysis; signal transduction

Indexed keywords

ANDROGEN RECEPTOR; CHEMOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; NOTCH RECEPTOR;

ADULT; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; EMBRYONIC STEM CELL; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; AGED; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PATHOLOGY; PROSTATECTOMY; PROSTATIC NEOPLASMS;

AGED; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LASER CAPTURE MICRODISSECTION; MALE; MIDDLE AGED; NEOPLASM GRADING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 80052083688     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21373     Document Type: Article

References (66)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60 (5): 277-300.
2. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A,. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360 (13): 1320-1328.
3. Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, Carroll PR,. The contemporary management of prostate cancer in the United States: Lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 2004; 171 (4): 1393-1401. (Pubitemid 38365382)
4. Mettlin C, Murphy GP, Babaian RJ, Chesley A, Kane RA, Littrup PJ, Mostofi FK, Ray PS, Shanberg AM, Toi A,. The results of a five-year early prostate cancer detection intervention. Investigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer 1996; 77 (1): 150-159.
5. Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ Jr, Yossepowitch O, Vickers AJ, Klein EA, Wood DP, Scardino PT,. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009; 27 (26): 4300-4305.
6. Bill-Axelson A, Holmberg L, Filen F, Ruutu M, Garmo H, Busch C, Nordling S, Haggman M, Andersson SO, Bratell S, Spangberg A, Palmgren J, Adami HO, Johansson JE,. Radical prostatectomy versus watchful waiting in localized prostate cancer: The Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008; 100 (16): 1144-1154.
7. Pierorazio PM, Guzzo TJ, Han M, Bivalacqua TJ, Epstein JI, Schaeffer EM, Schoenberg M, Walsh PC, Partin AW,. Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen. Urology 2010; 76 (3): 715-721.
8. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL,. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008; 300 (2): 173-181. (Pubitemid 351969301)
9. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL,. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18 (1): 11-22.
10. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM,. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007; 39 (1): 41-51. (Pubitemid 46026500)
11. Schaeffer EM, Marchionni L, Huang Z, Simons B, Blackman A, Yu W, Parmigiani G, Berman DM,. Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene 2008; 27 (57): 7180-7191.
12. True L, Coleman I, Hawley S, Huang CY, Gifford D, Coleman R, Beer TM, Gelmann E, Datta M, Mostaghel E, Knudsen B, Lange P, Vessella R, Lin D, Hood L, Nelson PS,. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci USA 2006; 103 (29): 10991-10996. (Pubitemid 44148406)
13. Pressinotti NC, Klocker H, Schafer G, Luu VD, Ruschhaupt M, Kuner R, Steiner E, Poustka A, Bartsch G, Sultmann H,. Differential expression of apoptotic genes PDIA3 and MAP3K5 distinguishes between low- and high-risk prostate cancer. Mol Cancer 2009; 8: 130.
14. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC,. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28 (3): 555-565. (Pubitemid 32916759)
15. McDonnell TJ, Chari NS, Cho-Vega JH, Troncoso P, Wang X, Bueso-Ramos CE, Coombes K, Brisbay S, Lopez R, Prendergast G, Logothetis C, Do KA,. Biomarker expression patterns that correlate with high grade features in treatment naive, organ-confined prostate cancer. BMC Med Genomics 2008; 1: 1.
16. Irizarry RA, Warren D, Spencer F, Kim IF, Biswal S, Frank BC, Gabrielson E, Garcia JG, Geoghegan J, Germino G, Griffin C, Hilmer SC, Hoffman E, Jedlicka AE, Kawasaki E, Martinez-Murillo F, Morsberger L, Lee H, Petersen D, Quackenbush J, Scott A, Wilson M, Yang Y, Ye SQ, Yu W,. Multiple-laboratory comparison of microarray platforms. Nat Methods 2005; 2 (5): 345-350.
17. Koupparis A, Gleave ME,. Multimodal approaches to high-risk prostate cancer. Curr Oncol 2010; 17 (Suppl 2): S33-S37.
18. Gan Y, Shi C, Inge L, Hibner M, Balducci J, Huang Y,. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Oncogene 2010; 29 (35): 4947-4958.
19. Antonarakis ES, Carducci MA, Eisenberger MA,. Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett 2010; 291 (1): 1-13.
20. Gildea JJ, Harding MA, Seraj MJ, Gulding KM, Theodorescu D,. The role of Ral A in epidermal growth factor receptor-regulated cell motility. Cancer Res 2002; 62 (4): 982-985. (Pubitemid 34160273)
21. Oosterhoff JK, Penninkhof F, Brinkmann AO, Anton Grootegoed J, Blok LJ,. REPS2/POB1 is downregulated during human prostate cancer progression and inhibits growth factor signalling in prostate cancer cells. Oncogene 2003; 22 (19): 2920-2925. (Pubitemid 36648918)
22. Gao T, Furnari F, Newton AC,. PHLPP: A phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 2005; 18 (1): 13-24. (Pubitemid 40444644)
23. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP,. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 2006; 441 (7092): 523-527. (Pubitemid 44050155)
24. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A,. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study. Lancet Oncol 2005; 6 (5): 279-286. (Pubitemid 40590264)
25. Mantovani A, Allavena P, Sica A, Balkwill F,. Cancer-related inflammation. Nature 2008; 454 (7203): 436-444.
26. Royuela M, Rodriguez-Berriguete G, Fraile B, Paniagua R,. TNF-alpha/IL-1/NF-kappaB transduction pathway in human cancer prostate. Histol Histopathol 2008; 23 (10): 1279-1290.
27. Collins CS, Hong J, Sapinoso L, Zhou Y, Liu Z, Micklash K, Schultz PG, Hampton GM,. A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. Proc Natl Acad Sci USA 2006; 103 (10): 3775-3780. (Pubitemid 43376631)
28. Tesz GJ, Guilherme A, Guntur KV, Hubbard AC, Tang X, Chawla A, Czech MP,. Tumor necrosis factor alpha (TNFalpha) stimulates Map4k4 expression through TNFalpha receptor 1 signaling to c-Jun and activating transcription factor 2. J Biol Chem 2007; 282 (27): 19302-19312. (Pubitemid 47100107)
29. Kulbe H, Hagemann T, Szlosarek PW, Balkwill FR, Wilson JL,. The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. Cancer Res 2005; 65 (22): 10355-10362. (Pubitemid 41743728)
30. Bailey CL, Kelly P, Casey PJ,. Activation of Rap1 promotes prostate cancer metastasis. Cancer Res 2009; 69 (12): 4962-4968.
31. Ischenko I, Seeliger H, Schaffer M, Jauch KW, Bruns CJ,. Cancer stem cells: How can we target them? Curr Med Chem 2008; 15 (30): 3171-3184.
32. Duhagon MA, Hurt EM, Sotelo-Silveira JR, Zhang X, Farrar WL,. Genomic profiling of tumor initiating prostatospheres. BMC Genomics 2010; 11: 324.
33. Konishi J, Yi F, Chen X, Vo H, Carbone DP, Dang TP,. Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim. Oncogene 2010; 29 (4): 589-596.
34. Zhang Y, Wang Z, Ahmed F, Banerjee S, Li Y, Sarkar FH,. Down-regulation of Jagged-1 induces cell growth inhibition and S phase arrest in prostate cancer cells. Int J Cancer 2006; 119 (9): 2071-2077. (Pubitemid 44423663)
35. Ross AE, Emadi A, Marchionni L, Hurley PJ, Simons BW, Schaeffer EM, Vuica-Ross M,. Dimeric naphthoquinones, a novel class of compounds with prostate cancer cytotoxicity. BJU Int 2010; Dec 22. [Epub ahead of print].
36. Sun Y, St Clair DK, Xu Y, Crooks PA, St Clair WH,. A NADPH oxidase-dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells. Cancer Res 2010; 70 (7): 2880-2890.
37. Sykiotis GP, Bohmann D,. Stress-activated cap'n'collar transcription factors in aging and human disease. Sci Signal 2010; 3 (112): re3.
38. Kang J, Gemberling M, Nakamura M, Whitby FG, Handa H, Fairbrother WG, Tantin D,. A general mechanism for transcription regulation by Oct1 and Oct4 in response to genotoxic and oxidative stress. Genes Dev 2009; 23 (2): 208-222.
39. Wang B, Hasan MK, Alvarado E, Yuan H, Wu H, Chen WY,. NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response. Oncogene 2010 Oct 18. [Epub ahead of print].
40. Zhang P, Singh A, Yegnasubramanian S, Esopi D, Kombairaju P, Bodas M, Wu H, Bova SG, Biswal S,. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther 2010; 9 (2): 336-346.
41. Feng S, Agoulnik IU, Bogatcheva NV, Kamat AA, Kwabi-Addo B, Li R, Ayala G, Ittmann MM, Agoulnik AI,. Relaxin promotes prostate cancer progression. Clin Cancer Res 2007; 13 (6): 1695-1702. (Pubitemid 46952934)
42. Guo Y, Kock K, Ritter CA, Chen ZS, Grube M, Jedlitschky G, Illmer T, Ayres M, Beck JF, Siegmund W, Ehninger G, Gandhi V, Kroemer HK, Kruh GD, Schaich M,. Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: Relation to long-term survival. Clin Cancer Res 2009; 15 (5): 1762-1769.
43. Kruh GD, Guo Y, Hopper-Borge E, Belinsky MG, Chen ZS,. ABCC10, ABCC11, and ABCC12. Pflugers Arch 2007; 453 (5): 675-684. (Pubitemid 46192538)
44. Simon JA, Lange CA,. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008; 647 (1-2): 21-29.
45. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM,. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419 (6907): 624-629.
46. Dai H, Li R, Wheeler T, Diaz de Vivar A, Frolov A, Tahir S, Agoulnik I, Thompson T, Rowley D, Ayala G,. Pim-2 upregulation: Biological implications associated with disease progression and perinueral invasion in prostate cancer. Prostate 2005; 65 (3): 276-286. (Pubitemid 41443733)
47. Schlomm T, Kirstein P, Iwers L, Daniel B, Steuber T, Walz J, Chun FH, Haese A, Kollermann J, Graefen M, Huland H, Sauter G, Simon R, Erbersdobler A,. Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res 2007; 13 (22 Pt 1): 6579-6584. (Pubitemid 350206791)
48. Ummanni R, Teller S, Junker H, Zimmermann U, Venz S, Scharf C, Giebel J, Walther R,. Altered expression of tumor protein D52 regulates apoptosis and migration of prostate cancer cells. FEBS J 2008; 275 (22): 5703-5713.
49. Wang R, Xu J, Mabjeesh N, Zhu G, Zhou J, Amin M, He D, Marshall FF, Zhau HE, Chung LW,. PrLZ is expressed in normal prostate development and in human prostate cancer progression. Clin Cancer Res 2007; 13 (20): 6040-6048. (Pubitemid 350075060)
50. Zhang H, Wang J, Pang B, Liang RX, Li S, Huang PT, Wang R, Chung LW, Zhau HE, Huang C, Zhou JG,. PC-1/PrLZ contributes to malignant progression in prostate cancer. Cancer Res 2007; 67 (18): 8906-8913. (Pubitemid 47437468)
51. Bibikova M, Chudin E, Arsanjani A, Zhou L, Garcia EW, Modder J, Kostelec M, Barker D, Downs T, Fan JB, Wang-Rodriguez J,. Expression signatures that correlated with Gleason score and relapse in prostate cancer. Genomics 2007; 89 (6): 666-672. (Pubitemid 46729630)
52. Miller GJ, Miller HL, van Bokhoven A, Lambert JR, Werahera PN, Schirripa O, Lucia MS, Nordeen SK,. Aberrant HOXC expression accompanies the malignant phenotype in human prostate. Cancer Res 2003; 63 (18): 5879-5888. (Pubitemid 37187488)
53. Ramachandran S, Liu P, Young AN, Yin-Goen Q, Lim SD, Laycock N, Amin MB, Carney JK, Marshall FF, Petros JA, Moreno CS,. Loss of HOXC6 expression induces apoptosis in prostate cancer cells. Oncogene 2005; 24 (1): 188-198. (Pubitemid 40143878)
54. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR,. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002; 1 (2): 203-209. (Pubitemid 41039166)
55. Wang J, Shiozawa Y, Wang Y, Jung Y, Pienta KJ, Mehra R, Loberg R, Taichman RS,. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem 2008; 283 (7): 4283-4294.
56. Hannigan A, Smith P, Kalna G, Lo Nigro C, Orange C, O'Brien DI, Shah R, Syed N, Spender LC, Herrera B, Thurlow JK, Lattanzio L, Monteverde M, Maurer ME, Buffa FM, Mann J, Chu DC, West CM, Patridge M, Oien KA, Cooper JA, Frame MC, Harris AL, Hiller L, Nicholson LJ, Gasco M, Crook T, Inman GJ,. Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. J Clin Invest 2010; 120 (8): 2842-2857.
57. Zhou J, Hernandez G, Tu SW, Scholes J, Chen H, Tseng CP, Hsieh JT,. Synergistic induction of DOC-2/DAB2 gene expression in transitional cell carcinoma in the presence of GATA6 and histone deacetylase inhibitor. Cancer Res 2005; 65 (14): 6089-6096. (Pubitemid 40994393)
58. Zhoul J, Hernandez G, Tu SW, Huang CL, Tseng CP, Hsieh JT,. The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer. Cancer Res 2005; 65 (21): 9906-9913. (Pubitemid 41541471)
59. Oosterhoff JK, Kuhne LC, Grootegoed JA, Blok LJ,. EGF signalling in prostate cancer cell lines is inhibited by a high expression level of the endocytosis protein REPS2. Int J Cancer 2005; 113 (4): 561-567. (Pubitemid 40038731)
60. Riddick AC, Shukla CJ, Pennington CJ, Bass R, Nuttall RK, Hogan A, Sethia KK, Ellis V, Collins AT, Maitland NJ, Ball RY, Edwards DR,. Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer 2005; 92 (12): 2171-2180. (Pubitemid 40966253)
61. Wang M, Liu YE, Greene J, Sheng S, Fuchs A, Rosen EM, Shi YE,. Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene 1997; 14 (23): 2767-2774. (Pubitemid 27313408)
62. Azar R, Alard A, Susini C, Bousquet C, Pyronnet S,. 4E-BP1 is a target of Smad4 essential for TGFbeta-mediated inhibition of cell proliferation. EMBO J 2009; 28 (22): 3514-3522.
63. Graff JR, Konicek BW, Lynch RL, Dumstorf CA, Dowless MS, McNulty AM, Parsons SH, Brail LH, Colligan BM, Koop JW, Hurst BM, Deddens JA, Neubauer BL, Stancato LF, Carter HW, Douglass LE, Carter JH,. eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Res 2009; 69 (9): 3866-3873.
64. Tamura K, Furihata M, Tsunoda T, Ashida S, Takata R, Obara W, Yoshioka H, Daigo Y, Nasu Y, Kumon H, Konaka H, Namiki M, Tozawa K, Kohri K, Tanji N, Yokoyama M, Shimazui T, Akaza H, Mizutani Y, Miki T, Fujioka T, Shuin T, Nakamura Y, Nakagawa H,. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res 2007; 67 (11): 5117-5125. (Pubitemid 46997247)
65. Ren C, Yang G, Timme TL, Wheeler TM, Thompson TC,. Reduced lysyl oxidase messenger RNA levels in experimental and human prostate cancer. Cancer Res 1998; 58 (6): 1285-1290. (Pubitemid 28183220)
66. Palamakumbura AH, Vora SR, Nugent MA, Kirsch KH, Sonenshein GE, Trackman PC,. Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling. Oncogene 2009; 28 (38): 3390-3400.